Hypha Labs and Tryptomics Launch Phase II of Strategic Partnership, Pairing Patented Mushroom Accelerator(TM) with World-Class Internal Quality Control & Fungal Genomics
Hypha Labs (OTCQB:FUNI) has launched Phase II of its strategic partnership with Tryptomics, combining Hypha's patented Mushroom Accelerator™ platform with Tryptomics' quality control and genomics services. The collaboration aims to develop proprietary bioreactor-optimized mushroom species and enhance quality assurance testing.
Key developments include the implementation of Tryptomics On-Site™ for in-house testing, third-party validation services, duplicate bioreactor deployment, and advanced genetics analysis through TryptoMatics™ and TryptoTyping™ technologies. The partnership enables rapid production of bioavailable Micro-Pearls in just 8 days, with the first new strains scheduled for launch in 2026.
Hypha Labs (OTCQB:FUNI) ha lanciato la Fase II della sua partnership strategica con Tryptomics, combinando la piattaforma brevettata Mushroom Accelerator™ di Hypha con i servizi di controllo qualità e genomica di Tryptomics. La collaborazione punta a sviluppare specie di funghi ottimizzate per bioreattori proprietarie e a migliorare i test di assicurazione della qualità.
Gli sviluppi chiave includono l'attuazione di Tryptomics On-Site™ per i test interni, servizi di convalida da parte di terzi, dispiegamento duplicato di bioreattori e analisi genetica avanzata attraverso le tecnologie TryptoMatics™ e TryptoTyping™. La partnership consente una rapida produzione di Micro-Pearls bio-disponibili in soli 8 giorni, con le prime nuove ceppi previste per il lancio nel 2026.
Hypha Labs (OTCQB:FUNI) ha lanzado la Fase II de su asociación estratégica con Tryptomics, combinando la plataforma patentada Mushroom Accelerator™ de Hypha con los servicios de control de calidad y genómica de Tryptomics. La colaboración busca desarrollar especies de setas optimizadas para bioreactores propietarias y mejorar las pruebas de aseguramiento de calidad.
Los desarrollos clave incluyen la implementación de Tryptomics On-Site™ para pruebas internas, servicios de validación por terceros, despliegue duplicado de bioreactores y análisis genético avanzado a través de las tecnologías TryptoMatics™ y TryptoTyping™. La asociación permite una producción rápida de Micro-Pearls bio-disponibles en solo 8 días, con las primeras nuevas cepas programadas para su lanzamiento en 2026.
Hypha Labs (OTCQB:FUNI)는 Tryptomics와의 전략적 파트너십 2단계(Phase II)를 시작했습니다. Hypha의 특허받은 Mushroom Accelerator™ 플랫폼과 Tryptomics의 품질 관리 및 유전체 서비스가 결합되어 있습니다. 협력은 독점적인 바이오리액터 최적화 버섯 종 개발과 품질 보증 테스트를 강화하는 것을 목표로 합니다.
주요 개발로는 내부 테스트를 위한 Tryptomics On-Site™의 구현, 제3자 검증 서비스, 이중 바이오리액터 배치, 그리고 TryptoMatics™ 및 TryptoTyping™ 기술을 통한 고급 유전 분석이 포함됩니다. 이 파트너십은 8일 만에 생체 이용 가능한 Micro-Pearls의 신속한 생산을 가능하게 하며, 새로운 첫 종은 2026년 출시를 예정하고 있습니다.
Hypha Labs (OTCQB:FUNI) a lancé la Phase II de son partenariat stratégique avec Tryptomics, combinant la plateforme brevetée Mushroom Accelerator™ d'Hypha avec les services de contrôle qualité et de génomique de Tryptomics. La collaboration vise à développer des espèces de champignons optimisées pour les bioreacteurs et à renforcer les essais d'assurance qualité.
Parmi les avancées clés figurent la mise en œuvre de Tryptomics On-Site™ pour les tests en interne, des services de validation tierce, le déploiement du bioreacteur en double et l'analyse génétique avancée via les technologies TryptoMatics™ et TryptoTyping™. Le partenariat permet une production rapide de Micro-Pearls biodisponibles en seulement 8 jours, les premières nouvelles souches étant prévues pour être lancées en 2026.
Hypha Labs (OTCQB:FUNI) hat Phase II seiner strategischen Partnerschaft mit Tryptomics gestartet und kombiniert Hyphas patentierte Plattform Mushroom Accelerator™ mit Tryptomics' Qualitätskontroll- und Genomikdiensten. Die Zusammenarbeit zielt darauf ab, proprietäre bioreaktoroptimierte Pilzarten zu entwickeln und die Qualitätssicherungstests zu verbessern.
Zu den wesentlichen Entwicklungen gehören die Implementierung von Tryptomics On-Site™ für interne Tests, Drittanbieter-Validierungsdienste, doppelte Bioreaktor-Bereitstellung sowie fortschrittliche Genomanalysen durch TryptoMatics™ und TryptoTyping™-Technologien. Die Partnerschaft ermöglicht die schnelle Produktion von bioverfügbaren Micro-Pearls in nur 8 Tagen, wobei die ersten neuen Stämme für den 2026-Rollout vorgesehen sind.
Hypha Labs (OTCQB:FUNI) أطلقت المرحلة الثانية من شراكتها الاستراتيجية مع Tryptomics، مجمّعة منصة Hypha الحاصلة على براءة اختراع Mushroom Accelerator™ مع خدمات مراقبة الجودة والجينوميات الخاصة بـ Tryptomics. التعاون يهدف إلى تطوير أنواع فطرية محسّنة للعمل في المفاعلات الحيوية ورفع اختبارات ضمان الجودة.
تشمل التطورات الرئيسية تنفيذ Tryptomics On-Site™ للاختبار الداخلي، وخدمات التحقق من خلال طرف ثالث، ونشر مفاعلين حيويين مكرر، والتحليل الوراثي المتقدم من خلال تقنيات TryptoMatics™ و TryptoTyping™. يتيح الشراكة إنتاجاً سريعاً لـ Micro-Pearls المتاحة حيوياً في غضون 8 أيام، مع الجدولة لإطلاق السلالات الجديدة الأولى في 2026.
Hypha Labs (OTCQB:FUNI) 已启动与 Tryptomics 的战略伙伴关系第 II 阶段，将 Hypha 的专利 Mushroom Accelerator™ 平台与 Tryptomics 的质量控制和基因组学服务相结合。该合作旨在开发适用于生物反应器的专有蘑菇种类并提升质量保证测试。
关键进展包括为内部测试实施 Tryptomics On-Site™、第三方验证服务、双重生物反应器部署，以及通过 TryptoMatics™ 和 TryptoTyping™ 技术进行的高级基因分析。合作关系使在仅 8 天 内实现可生物利用的 Micro-Pearls 的快速生产，首批新菌株计划于 2026 推出。
- Reduced production time to 8 days for bioavailable Micro-Pearls production
- Implementation of advanced quality control and third-party validation systems
- Development of proprietary mushroom strains with enhanced bioreactor optimization
- Expansion from consumer devices to large-scale ingredient production capabilities
- New strains won't be available until 2026
- Currently conducting Regulation A+ offering, indicating potential dilution for existing shareholders
LAS VEGAS, NV, NV / ACCESS Newswire / October 1, 2025 / Hypha Labs, Inc. (OTCQB:FUNI), a biotechnology company pioneering the development of functional mushroom technologies, today announced the official launch of Phase II in its strategic partnership with Tryptomics, uniting Hypha's patented Mushroom Accelerator™ platform with Tryptomics On-Site™ Science Services & their contract R&D Metabolomics Pipeline to develop Hypha Labs proprietary varieties of bioreactor-optimized species and providing the gold-standard in quality assurance testing at Hypha Labs. The collaboration accelerates R&D cycles and advances the future of at-home, pharmaceutical-grade mushroom wellness.
Phase I introduced a dual-track approach to validation and scalability:
Tryptomics On-Site™: Hypha Labs has accelerated its in-house analytical testing capabilities by partnering with Tryptomics to implement their in-depth analytical testing methods to optimize the accelerator's production.
Third-Party Verification Role: Tryptomics serves as an independent validation lab, confirming Hypha's internal results through Certificate of Analysis (COA) verification and reproducibility benchmarking.
Bioreactor Deployment & Duplication: Tryptomics has been equipped to deploy and operate duplicate Mushroom Accelerators™ in-house, mirroring Hypha Lab's systems for synchronized experimentation and protocol testing.
Genetics Collaboration: Through discussions and planning, Hypha Labs and Tryptomics is excited to announce the advancement of its mycology program through Tryptomics' next-generation sequencing analyses, TryptoMatics™ and marker assisted breeding, TryptoTyping™.
The program also targets rapid, reproducible production of bioavailable Micro-Pearls in just eight days, providing faster iteration and scalability. With third-party COAs and internal quality control forthcoming, the first new strains are scheduled to launch in 2026 making the biochemistry of mycelium available to the wider population.
Phase II Highlights
Tryptomics On-Site™ provides state-of-the-art in-house production QC testing
TryptoMatics™ & TryptoTyping™ provides advanced genetics analysis and quality assurance
Third Party QC Analysis provides Hypha Labs with the ability to dig deeper
Mushroom Accelerator™ enables 8-day micro-ingredient production
Duplicate bioreactors deployed for synchronized R&D
First new bioreactor-optimized strains launching in 2026
"This strategic partnership aligns Hypha Labs' proprietary cultivation technology with Tryptomics' Metabolomics Pipeline to provide scalable and quality assured mushroom supplements to society," said Caleb King, Chief Science Officer and Cofounder of Tryptomics.
"Tryptomics brings the most diverse skillset under one roof and this sets us up to lead the next wave of biotech wellness," said Craig Ellins, Chief Science Officer, Hypha Labs. "Our Phase II partnership expands both speed and credibility-accelerating discovery while ensuring every result is independently validated."
Hypha Labs is currently conducting a Regulation A+ public offering, providing early investors with the opportunity to participate in the company's growth as it expands from consumer-focused devices to large-scale ingredient production.
For details on the Reg A+ campaign, visit: Invest.hyphalabs.com
About Tryptomics
Tryptomics is an early-stage biotechnology company advancing the science of natural products through cutting-edge testing services and proprietary technologies. We integrate advanced analytical chemistry with next-generation sequencing to accelerate discovery and enable Personalized Natural Medicine™. Our platform delivers comprehensive chemical and genetic testing across medicinal plants, fungi, and other natural matrices, supporting the development of APIs, nutraceuticals, and novel therapeutic formulations. By combining rigorous science with scalable technology, Tryptomics empowers cultivators, researchers, and product developers to innovate with greater speed, safety, and reproducibility. Visit Us at Tryptomics.com
About Hypha Labs, Inc.
The company has developed revolutionary, cutting-edge technology focused on new methods of producing the active ingredients found in a wide array of functional mushrooms using its patent-pending mushroom accelerators. The Company is positioning itself to play an important role in the burgeoning Functional Mushroom industry in addition to being a disruptive force in future and emerging mushroom opportunities. Visit us at HyphaLabs.com.
SAFE HARBOR FORWARD LOOKING STATEMENTS:
This press release may contain forward looking statements that are based on current expectations, forecasts, and assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues related to our financial performance, expected revenue, contracts, and future growth for upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC) and on the OTC Disclosure & News Service (OTCDNS). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in our filings with the SEC and/or OTCDNS. Among other matters, the Company may not be able to sustain growth or achieve profitability based upon many factors including but not limited to the risk that we will not be able to find and secure construction contracts and the necessary assets that will enable us to become profitable. Reference is hereby made to cautionary statements set forth in the Company's most recent SEC and/or OTCDNS filings. We have incurred and will continue to incur significant expenses in our development stage, noting that there is no assurance that we will generate enough revenues to offset those costs in both the near and long term. New lines of business in the construction industry may expose us to additional legal and regulatory costs and unknown exposure(s), the impact of which cannot be predicted at this time. Words such as "estimate," "project," "predict," "will," "would," "should," "could," "may," "might," "anticipate," "plan," "intend," "believe," "expect," "aim," "goal," "target," "objective," "likely" or similar expressions that convey the prospective nature of events or outcomes generally indicate forward-looking statements. You should not place undue reliance on these forward-looking statements, which speak only as of this press release. Unless legally required, we undertake no obligation to update, modify or withdraw any forward-looking statements, because of new information, future events or otherwise.
From time to time, the Company may post new and material information on its website or through its social media profiles at the links below:
LN: https://www.linkedin.com/company/hypha-labs-inc/
FB: https://www.facebook.com/hyphalabs
IG: https://www.instagram.com/hyphalabsinc/
Twitter: https://x.com/Hypha_Labs
For more information about Hypha Labs visit HyphaLabs.com
For the Company's current Investor Presentation please visit www.HyphaLabs.com/deck
Investor and Media Relations:
Integrity Media Inc.
(888) 216-3595
team@integritymedia.com
SOURCE: Hypha Labs, Inc.
View the original press release on ACCESS Newswire
FAQ
What is the significance of Hypha Labs' Phase II partnership with Tryptomics for FUNI stock?
When will Hypha Labs (FUNI) launch its new bioreactor-optimized mushroom strains?
What technologies are included in the Hypha Labs and Tryptomics partnership?
How does Hypha Labs' Regulation A+ offering affect investors?
What is the production timeline for Hypha Labs' Micro-Pearls using the Mushroom Accelerator?
